GlassScriptPhysician profile
Christopher Ljucovic
NPI 1942578968
$959.49
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $638 · 2022: $321.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $134.93 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $129.65 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $117.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.02 | 2021-2022 | |
| Incyte Corporation | $86.18 | 2022 | |
| Kaleo, INC. | $76.39 | 2021 | |
| Biocryst US Sales Co., LLC | $64.60 | 2021-2022 | |
| Amgen INC. | $55.96 | 2021-2022 | |
| Optinose US, INC. | $55.01 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $36.88 | 2021 | |
| Glaxosmithkline, LLC. | $34.08 | 2021 | |
| Horizon Therapeutics Plc | $18.93 | 2022 | |
| Pfizer INC. | $13.37 | 2021 | |
| Aytu Biopharma, INC. | $13.24 | 2021 | |
| Alk-Abello, INC | $11.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ljucovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.